The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

被引：19
|
作者：
Gozzetti, Alessandro [1 ]
Capochiani, Enrico [2 ]
Bocchia, Monica [1 ]
机构：
[1] Univ Siena, Div Hematol, Siena, Italy
[2] Azienda USL Toscana NordOvest, Ctr Translat Med, Hematol Unit, Livorno, Italy
来源：
LEUKEMIA | 2020年 / 34卷 / 10期
关键词：
D O I：
10.1038/s41375-020-01038-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2815 / 2816
页数：2
相关论文
共 50 条
  • [1] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
    Alessandro Gozzetti
    Enrico Capochiani
    Monica Bocchia
    Leukemia, 2020, 34 : 2815 - 2816
  • [2] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    F. La Rosée
    H. C. Bremer
    I. Gehrke
    A. Kehr
    A. Hochhaus
    S. Birndt
    M. Fellhauer
    M. Henkes
    B. Kumle
    S. G. Russo
    P. La Rosée
    Leukemia, 2020, 34 : 1805 - 1815
  • [3] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    La Rosee, F.
    Bremer, H. C.
    Gehrke, I
    Kehr, A.
    Hochhaus, A.
    Birndt, S.
    Fellhauer, M.
    Henkes, M.
    Kumle, B.
    Russo, S. G.
    La Rosee, P.
    LEUKEMIA, 2020, 34 (07) : 1805 - 1815
  • [4] Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
    Verstovsek, Srdan
    POSTGRADUATE MEDICINE, 2013, 125 (01) : 128 - 135
  • [5] Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
    Praveen, D.
    Puvvada, Ranadheer Chowdary
    Aanandhi, Vijey M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
  • [6] The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    La Rosee, F.
    Bremer, H. -C.
    Hochhaus, A.
    Birndt, S.
    Fellhauer, M.
    Henkes, M.
    Russo, S. G.
    La Rosee, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 198 - 198
  • [7] An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
    Wysham, Nicholas G.
    Sullivan, Donald R.
    Allada, Gopal
    CHEST, 2013, 143 (05) : 1478 - 1479
  • [8] An experience with ruxolitinib, a Janus Kinase 1 and 2 inhibitor, in the management of patients with myeloproliferative neoplasms
    Raza, K.
    Murphy, P.
    Quinn, J.
    Sargent, J.
    Thornton, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 133 - 133
  • [9] Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor
    Kinoshita, Manao
    Ogawa, Youichi
    Kawamura, Tatsuyoshi
    Kirito, Keita
    Shimada, Shinji
    JOURNAL OF DERMATOLOGY, 2016, 43 (11): : 1387 - 1388
  • [10] Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
    Finsterer, Josef
    Scorza, Fulvio A.
    BRAIN HEMORRHAGES, 2021, 2 (04): : 151 - 152
12345